Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is a financially sound company with a strong first quarter that is transitioning to the pharmacy channel for increased profits. However, there are some uncertainties and potential risks that could affect short-term estimates. The company's success in converting patients to the pharmacy channel and maintaining favorable economics will be crucial for their future growth and profitability. Its lower margins and potential execution risks may result in a discounted valuation compared to its peers.

Bears say

Tandem Diabetes Care is facing risks to its growth potential due to the slow conversion of its existing patient base to the new pharmacy channel, as well as potential headwinds from the competition as they introduce new products. While the company is projecting revenue growth in the mid-single digits for FY26, it remains to be seen if they can successfully transition to a pay-as-you-go model and secure access to the pharmacy channel. Additionally, the international market presents a significant opportunity for growth, with potential annual renewal revenue of $100M+, but the company's plan to convert 70-80% of its existing US patient base to the pharmacy channel within 2-3 years may be too aggressive. Therefore, the financial analyst has a negative outlook for Tandem Diabetes Care's stock.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.